Olanzapine Versus An Active Comparator in the Treatment of Schizophrenia

July 18, 2006 updated by: Eli Lilly and Company
The purpose of this study is to determine how Olanzapine compares to an active comparator in the treatment of schizophrenia

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment

530

Phase

  • Phase 4

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Argentina
      • Buenos Aires, Argentina
      • Ciudad De Buenos Air, Argentina
    • Buenos Aires
      • La Plata, Buenos Aires, Argentina
    • Mendoza
      • Godoy Cruz, Mendoza, Argentina
  • Austria
      • Graz, Austria
      • Innsbruck, Austria
      • Linz, Austria
      • Wein, Austria
      • Wels, Austria
  • Brazil
      • Rio De Janeiro, Brazil
      • Sau Paulo, Brazil
    • Bahia
      • Salvador, Bahia, Brazil
    • Goias
      • Aparecida De Goiania, Goias, Brazil
    • RS
      • Pelotas, RS, Brazil
  • Germany
      • Essen, Germany
      • Hamburg, Germany
      • Tubingen, Germany
  • Ireland
      • Dublin, Ireland
  • Mexico
      • Mexico City, Mexico
  • Peru
      • Lima, Peru
  • Puerto Rico
      • Cidra, Puerto Rico
      • Ponce, Puerto Rico
      • Rio Piedras, Puerto Rico
      • San Juan, Puerto Rico
  • Spain
      • Barcelona, Spain
    • Asturias
      • Sama De Langreo, Asturias, Spain
    • Barcelona
      • San Boi De Llobregat, Barcelona, Spain
    • Navarra
      • Elizondo, Navarra, Spain
      • Pamplona, Navarra, Spain
  • United Kingdom
      • London, United Kingdom
    • London
      • Camberwell, London, United Kingdom
    • Norfolk
      • Kings Lynn, Norfolk, United Kingdom
    • Scotland
      • Paisley, Scotland, United Kingdom
    • Surrey
      • Guildford, Surrey, United Kingdom
  • United States
    • California
      • El Centro, California, United States
      • Glendale, California, United States
      • Sherman Oaks, California, United States
    • Connecticut
      • Middleton, Connecticut, United States
      • Norwich, Connecticut, United States
    • Florida
      • Melbourne, Florida, United States
      • Miami, Florida, United States
    • Georgia
      • Atlanta, Georgia, United States
    • Illinois
      • Chicago, Illinois, United States
      • Hoffman Estates, Illinois, United States
    • Indiana
      • Lafayette, Indiana, United States
    • Maryland
      • Rockville, Maryland, United States
    • Massachusetts
      • Newton, Massachusetts, United States
    • Missouri
      • St Charles, Missouri, United States
    • New York
      • New York, New York, United States
      • Olean, New York, United States
      • Staten Island, New York, United States
    • Ohio
      • Cincinnati, Ohio, United States
    • Oregon
      • Portland, Oregon, United States
    • Pennsylvania
      • Philadelphia, Pennsylvania, United States
    • Texas
      • Austin, Texas, United States
      • El Paso, Texas, United States
      • Houston, Texas, United States
      • Terrell, Texas, United States
    • Virginia
      • Richmond, Virginia, United States
  • Venezuela
      • Caracas, Venezuela

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 75 years (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion:

  1. You must be between the ages of 18 and 75. If you have reached your 76th birthday, you will not be able to participate
  2. You must have been diagnosed with schizophrenia
  3. You must be able to visit the doctor's office as scheduled for the next 7 months

Exclusion:

  1. You have a serious medical illness, such as heart, liver, or kidney disease (Note: If you are uncertain about a particular condition, discuss it with your doctor.)
  2. You are either pregnant or breastfeeding

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Eli Lilly and Company

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

August 1, 2001

Study Completion

July 1, 2002

Study Registration Dates

First Submitted

May 7, 2002

First Submitted That Met QC Criteria

May 7, 2002

First Posted (Estimate)

May 8, 2002

Study Record Updates

Last Update Posted (Estimate)

July 19, 2006

Last Update Submitted That Met QC Criteria

July 18, 2006

Last Verified

July 1, 2006

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2347
  • F1D-MC-HGHJ

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Schizophrenia

Clinical Trials on Olanzapine

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Nigeria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe